EN DE
STOCK COMPARISON

GlaxoSmithKline Pharmaceuticals vs Eli Lilly and: Fair Value & Quality

Both stocks run through our valuation models. Here is how GlaxoSmithKline Pharmaceuticals (GLAXO) and Eli Lilly and (LLY) compare, as of Aug 17, 2026.

As of Aug 17, 2026, Fair Value Calculator sees GlaxoSmithKline Pharmaceuticals as the less overvalued of the two: GlaxoSmithKline Pharmaceuticals trades at ₹2,689 versus a fair value of ₹960 (-64%), while Eli Lilly and trades at $1,180 versus $389 (-67%).
GlaxoSmithKline Pharmaceuticals
GLAXO.NSE · INR · Health Care
-64%
upside to fair value
overvalued
Price₹2,689
Fair Value₹960
Quality80/100
Eli Lilly and
LLY · USD · Health Care
-67%
upside to fair value
overvalued
Price$1,180
Fair Value$389
Quality69/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

GlaxoSmithKline PharmaceuticalsEli Lilly and
Valuation
44.0×P/E (TTM)42.2×
10.71×P/S (TTM)14.67×
18.05×P/B39.94×
31.0×EV/EBITDA30.2×
—PEG1.54×
2.3%Dividend yield0.5%
₹57.00Dividend per share$6.23
Profitability
27%Net margin35%
34%Operating margin49%
49%Return on equity107%
19%Return on assets21%
Growth
2%Revenue growth (YoY)56%
5.8%Avg. growth/yr (3Y)31.7%
5.7%Avg. growth/yr (5Y)21.6%
Balance & size
—Debt / equity1.54×
$4BMarket cap$1.1T
healthyGrowth qualitymixed

Eli Lilly and leads: 3 to 9 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

GlaxoSmithKline Pharmaceuticalsof which business quality 78 · market factors 58 Eli Lilly andof which business quality 65 · market factors 81
ProfitabilityMargins and returns on capital today
87
85
Quality GrowthAre margins and returns improving?
41
86
CashflowEarnings quality: real cash, not paper profit
81
51
Fin. StrengthBalance sheet, leverage, solvency risk
92
53
InvestmentDisciplined investing over empire-building
69
15
Low VolatilityCalm price path (market factor)
91
77
MomentumPrice trend over the last 3–12 months (market factor)
45
76
52W MomentumDistance to the 52-week high (market factor)
42
95
Net IssuanceBuybacks instead of dilution
82
93

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

GlaxoSmithKline Pharmaceuticals

DCF Models₹1,074
Earnings-Based₹683
Dividend Discount₹667
Multiples₹975
Asset-Based₹89.68
Growth DCF₹923
Economic Profit₹599
Growth Earnings₹1,088

25 of 25 models see the stock below the current price.

Eli Lilly and

DCF Models$334
Earnings-Based$239
Dividend Discount$115
Multiples$358
Asset-Based$19.94
Growth DCF$187
Economic Profit$347
Growth Earnings$375

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

GlaxoSmithKline Pharmaceuticals
Bear ₹675Fair Value ₹960Bull ₹1,414
₹2,689 = current price (white tick)
Eli Lilly and
Bear $216Fair Value $389Bull $582
$1,180 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

GlaxoSmithKline Pharmaceuticals · Health Care

Quality score80 · Top 25%
Fair value upside-64% · bottom 25%

Eli Lilly and · Health Care

Quality score69 · Top 25%
Fair value upside-67% · bottom 25%

Bottom line

As of Aug 17, 2026, Fair Value Calculator sees GlaxoSmithKline Pharmaceuticals as the less overvalued of the two: GlaxoSmithKline Pharmaceuticals trades at ₹2,689 versus a fair value of ₹960 (-64%), while Eli Lilly and trades at $1,180 versus $389 (-67%).

GlaxoSmithKline Pharmaceuticals has the higher quality score (80/100).

See the full analysis →
GlaxoSmithKline Pharmaceuticals · Eli Lilly and

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to GlaxoSmithKline Pharmaceuticals

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Eli Lilly and

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.